AKT1 and Alzheimer disease: Moreover, there is a substantial 70% decrease in ethanolamine plasmalogens (PlsEtns) in AD patients, which exert neuroprotective effects by activating G-protein coupled receptors (GPCRs), increasing AKT and ERK pathway phosphorylation, preventing neuronal death, reducing γ-secretase activity, and decreasing Aβ production [73, 74].